Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05378334 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Mar 1, 2024 to Sep 1, 2027
    • Study completion date: Mar 1, 2025 to Jan 1, 2028
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 1, 2022 to Jun 15, 2022
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a double-blind, randomized controlled study evaluating the efficacy and safety of HGXJT in combination with ICI-based standard treatment in lung cancer patients with bone metastases. Enrolled participates will randomly receive HGXJT or placebo during the first 4-6 cycles of ICI-based standard treatment.
Trial Details
NCT Number NCT05378334
Lead Sponsor Guangzhou University of Traditional Chinese Medicine
Conditions
(from sponsor)		 Non-small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 82 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov